146 related articles for article (PubMed ID: 16103482)
1. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Robert C; Faivre S; Raymond E; Armand JP; Escudier B
Ann Intern Med; 2005 Aug; 143(4):313-4. PubMed ID: 16103482
[No Abstract] [Full Text] [Related]
2. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
3. Drug essentials. Small molecule multitargeted TKI therapy.
Wilkes GM
Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):47-8. PubMed ID: 19856581
[No Abstract] [Full Text] [Related]
4. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
5. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
6. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A
Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of anticancer agents that target the VEGF pathway.
Chen HX; Cleck JN
Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
[TBL] [Abstract][Full Text] [Related]
8. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
9. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
11. Multi-kinase inhibitors create buzz at ASCO.
Branca MA
Nat Biotechnol; 2005 Jun; 23(6):639. PubMed ID: 15940222
[No Abstract] [Full Text] [Related]
12. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
Hipp MM; Hilf N; Walter S; Werth D; Brauer KM; Radsak MP; Weinschenk T; Singh-Jasuja H; Brossart P
Blood; 2008 Jun; 111(12):5610-20. PubMed ID: 18310500
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Shaheen PE; Rini BI; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
[TBL] [Abstract][Full Text] [Related]
15. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Huang Y; Wang Y; Li Y; Guo K; He Y
J Cancer Res Clin Oncol; 2011 May; 137(5):829-37. PubMed ID: 20809412
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Vogl UM; Berger W; Micksche M; Pirker C; Lamm W; Pichelmeyer O; Zielinski CC; Schmidinger M
Cancer Lett; 2009 May; 277(2):218-26. PubMed ID: 19171421
[TBL] [Abstract][Full Text] [Related]
18. Combination of target agents: challenges and opportunities.
Ardizzoni A; Tiseo M
J Thorac Oncol; 2007 May; 2(5 Suppl):S4-6. PubMed ID: 17457232
[No Abstract] [Full Text] [Related]
19. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
20. ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Michaelson MD
Cancer Treat Rev; 2007 Jun; 33(4):381-90. PubMed ID: 17367939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]